Pemetrexed: An active new agent for breast cancer

Seminars in Oncology

Volumn 29, Issue 6 SUPPL. 18, 2002, Pages 57-62

  O'Shaughnessy, Joyce A ^a  

^a Developmental Therapeutics Committee and Co Chair of the Genitourinary Committee   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTHRACYCLINE DERIVATIVE; ANTINEOPLASTIC AGENT; CAPECITABINE; CISPLATIN; CYANOCOBALAMIN; CYCLOPHOSPHAMIDE; DEXAMETHASONE; DIHYDROFOLATE REDUCTASE; DOXORUBICIN; FOLIC ACID; GEMCITABINE; NAVELBINE; PACLITAXEL; PEMETREXED; PHOSPHORIBOSYLGLYCINAMIDE FORMYLTRANSFERASE; TAXANE DERIVATIVE; THYMIDYLATE SYNTHASE;

ALOPECIA; ANTINEOPLASTIC ACTIVITY; BLOOD TOXICITY; BONE MARROW SUPPRESSION; BREAST CANCER; CANCER COMBINATION CHEMOTHERAPY; CLINICAL TRIAL; CROSS RESISTANCE; CYTOTOXICITY; DIARRHEA; DRUG MECHANISM; DRUG METABOLISM; DRUG TOLERABILITY; HUMAN; INTERPHASE; LIVER DYSFUNCTION; NAUSEA; NEUTROPENIA; PRIORITY JOURNAL; RASH; REVIEW; SKIN TOXICITY; STOMATITIS; THROMBOCYTOPENIA; VITAMIN SUPPLEMENTATION; VOMITING;

EID: 0036984217     PISSN: 00937754     EISSN: None     Source Type: Journal    
DOI: 10.1053/sonc.2002.37474     Document Type: Review

References (16)

1. Hortobagyi GN: Developments in chemotherapy of breast cancer. Cancer 88:3073-3079, 2000 (suppl 12)
2. Chen VJ, Bewley JR, Gossett L, et al: Activity of LY231514 against several enzymes in the folate-dependent pathways. Proc Am Assoc Cancer Res 37:388, 1996 (abstr 2598)
3. O'Shaughnessy JA, Gennari A, Conte P: Pemetrexed: A promising new treatment for breast cancer. Semin Oncol 29: 36-41, 2002 (suppl 5)
4. Cripps MC, Burnell M, Jolivet J, et al: Phase II study of a multi-targeted antifolate (LY231514) (MTA) as first line therapy in patients with locally advanced or metastatic colorectal cancer (MCC). Eur J Cancer 33:ECCO9, 1997 (suppl 8) (abstr 768)
5. Rusthoven JJ, Eisenhauer E, Butts C, et al: Multitargeted antifolate LY231514 as first-line chemotherapy for patients with advanced non-small-cell lung cancer: A phase II study. J Clin Oncol 17:1194-1199, 1999
6. Miller KD, Loehrer PJ, Picus J, et al: Phase II study of the multitargeted antifolate LY231514 (ALIMTA, MTA, pemetrexed disodium) in patients with advanced pancreatic cancer. Ann Oncol 11:101-103, 2000
7. Henderson IC, Berry D, Demetri G, et al: Improved disease-free (DFS) and overall survival (OS) from the addition of sequential paclitaxel (T) but not from the escalation of doxorubicin (A) dose level in the adjuvant chemotherapy of patients (pts) with node-positive primary breast cancer (BC). Proc Am Soc Clin Oncol 17:101a, 1998 (abstr 309)
8. Nabholtz JM: Phase III trial comparing TAC (docetaxel, doxorubicin, cyclophosphamide) with FAC (5-fluorouracil, doxorubicin, cyclophosphamide) in the adjuvant treatment of node positive breast cancer (BC) patients: Interim analysis of the BCIRG 001 study. Proc Am Soc Clin Oncol 21:36a, 2002 (abstr 141)
9. Vogelzang NJ, Rusthoven J, Paoletti P, et al: Phase III single-blinded study of pemetrexed and cisplatin vs. cisplatin alone in chemonaive patients with malignant pleural mesothelioma. Proc Am Soc Clin Oncol 21:2a, 2002 (abstr 5)
10. Bunn P, Paoletti P, Niyikiza C, et al: Vitamin B12 and folate reduce toxicity of Alimta (pemetrexed disodium, LY231514, MTA), a novel antifolate/antimetabolite. Proc Am Soc Clin Oncol 20:76a, 2001(abstr 300)
11. Miles DW, Smith IE, Coleman RE, et al: A phase II study of pemetrexed disodium (LY231514) in patients with locally recurrent or metastatic breast cancer. Eur J Cancer 37:1366-1371, 2001
12. Spielmann M, Martin M, Namer M, et al: Activity of pemetrexed (ALIMTA, multitargeted antifolate, LY231514) in metastatic breast cancer patients previously treated with an anthracycline and a taxane: An interim analysis. Clin Breast Cancer 2:47-51, 2001
13. Llombart-Cussac A, Theodoulou M, Rowland K, et al: A phase II trial of pemetrexed disodium (LY231514, MTA) in metastatic breast cancer (MBC) patients who have failed anthracyclines (A) and taxanes (T) (salvage chemotherapy). Breast Cancer Res Treat 64:120a, 2000 (abstr 526)
14. Mennel RG, O'Shaughnessy JA, Blum JL, et al: Pemetrexed disodium (ALIMTA, LY231514, MTA) in advanced breast cancer (ABC) patients (pts) with prior anthracycline or anthracenedione, taxane, and capecitabine treatment: A phase II study. Proc Am Soc Clin Oncol 20:49a, 2001 (abstr 194)
15. Hughes A, Lind M, Azzabi A, et al. A phase I dose escalation study of doxorubicin in combination with pemetrexed (Alimta, multitargeted antifolate). Breast Cancer Res Treat 69:286, 2001 (abstr 438)
16. Tonkinson JL, Wagner MM, Paul DC, et al: Cell cycle modulation by the multi-targeted anti-folate, LY231514, increases the antiproliferative activity of gemcitabine. Proc Am Assoc Cancer Res 37:370, 1996 (abstr 2523)